Diarrhea News and Research

Latest Diarrhea News and Research

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech announces the pricing for ROTAVAC vaccine

New E. coli outbreak alarms Europe

New E. coli outbreak alarms Europe

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

BGI genome sequencing identifies new super-toxic bacteria as cause of current European epidemic

BGI genome sequencing identifies new super-toxic bacteria as cause of current European epidemic

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

American College of Gastroenterology offers resources on foodborne illness, tips for food safety

American College of Gastroenterology offers resources on foodborne illness, tips for food safety

New approach for treatment of infections of urinary tract

New approach for treatment of infections of urinary tract

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

Mass vaccination strategy could prevent future cholera epidemics in Zimbabwe

Mass vaccination strategy could prevent future cholera epidemics in Zimbabwe

New Kaiser Family Foundation tool shows which global health interventions are working

New Kaiser Family Foundation tool shows which global health interventions are working

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

E. coli bacterial research articles now available for free on SpringerLink

E. coli bacterial research articles now available for free on SpringerLink

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Scientists find increases in rain and temperature could signal deadly cholera outbreaks months before they strike

Scientists find increases in rain and temperature could signal deadly cholera outbreaks months before they strike

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Complementary technologies for rapid EHEC identification and detection

Complementary technologies for rapid EHEC identification and detection

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.